During Wednesday’s Current trade, Shares of Baxalta Inc (NYSE:BXLT), lost -0.29% to $34.51.
Baxalta Incorporated (BXLT), a global biopharmaceutical leader dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions, recently declared that the company has accomplished the acquisition of the ONCASPAR (pegaspargase) portfolio from Sigma-Tau Finanziaria S.p.A. The acquisition comprises ONCASPAR, an important biologic treatment for patients with acute lymphoblastic leukemia (ALL), the novel investigational biologic calaspargase pegol, and established global clinical and commercial resources. Baxalta formerly declared plans to acquire the portfolio for about $900 million.
ONCASPAR is a biologic cancer therapy used as a component of multi-agent chemotherapeutic regimens to treat acute lymphoblastic leukemia (ALL), a rapidly progressing cancer of the white blood cells responsible for more than 80 percent of childhood leukemia cases. Standard of care regimens are highly effective in treating more than 80 percent of pediatric ALL patients in the United States.1
Baxalta Incorporated, a biopharmaceutical company, develops, manufactures, and markets a portfolio of products primarily for the treatment of hematology and immunology worldwide. It also offers other therapies for the treatments of bleeding disorders, and chronic and acute medical conditions, counting hemophilia A, hemophilia B, attained hemophilia, inhibitor treatments, primary immunodeficiency (PID), and alpha-1 antitrypsin deficiency.
Shares of Integrated Device Technology Inc (NASDAQ:IDTI), inclined 0.54% to $18.57, during its current trading session.
Integrated Device Technology, Inc. (IDTI) declared its selection of foundry-segment leader TSMC as recipient of a Planned Partnership Award for its support of recent IDT product rollouts. IDT executives presented a plaque to TSMC North America leadership at IDT’s San Jose headquarters in a ceremony attended by executives from both companies.
Integrated Device Technology, Inc. designs, develops, manufactures, and markets a range of semiconductor solutions for the communications, computing, and consumer industries worldwide. It operates in two segments, Communications, and Computing and Consumer. The Communications segment offers communication timing products, such as clocks and timing solutions; flow-control administration devices comprising Serial RapidIO switching solutions; multi-port products; telecommunications products; static random access memory products; first in and first out memories; digital logic products; radio frequency products; and MEMS oscillator solutions .
Aetna Inc (NYSE:AET), during its Wednesday’s current trading session gained 0.02% to $111.57.
Aetna (NYSE: AET) declared second-quarter 2015 operating earnings (1) of $722.1 million, or $2.05 per share, a per-share enhance of 21 percent over the second quarter of 2014. Net income (2) for the second quarter of 2015 was $731.8 million, or $2.08 per share.
Total company results
- Operating earnings (1)were $722.1 million for the second quarter of 2015 contrast with $610.0 million for the second quarter of 2014. The 18 percent enhance in operating earnings is primarily due to higher underwriting margins in Aetna’s Health Care segment, partially offset by an enhance in general and administrative expenses.
- Net income (2)was $731.8 million for the second quarter of 2015 contrast with $548.8 million for the second quarter of 2014. Net income in both periods reflects net benefits (charges).
- Operating revenues(3) were $15.1 billion for the second quarter of 2015 contrast with $14.5 billion for the second quarter of 2014. The 4 percent enhance in operating revenues is primarily the result of higher Health Care premium yields in addition to membership growth in Aetna’s Government business partially offset by membership losses in Aetna’s middle-market Commercial Insured products. Total revenue was $15.2 billion and $14.5 billion for the second quarters of 2015 and 2014, respectively. Total revenue for the second quarter of 2015 comprises about $110 million of net litigation-related proceeds.
Aetna Inc. operates as a health care benefits company in the United States. It operates through three segments: Health Care, Group Insurance, and Large Case Pensions. The Health Care segment offers medical, pharmacy benefit administration services, dental, behavioral health, and vision plans on an insured basis, and an employer-funded or administrative basis.
Finally, ConAgra Foods Inc (NYSE:CAG), gained 0.17%, to $40.94.
ConAgra Foods, Inc. (CAG) declared the search for a spokesperson recently who embodies the brand’s lasting philosophy of creating special, just-like-homemade desserts that nurture friends and family. Through a month-long talent search, Marie Callender’s will identify its “Pie Queen or King,” an individual who will serve as the brand’s spokesperson and winner of a $15,000 grand prize to make his or her baking dreams come true.
ConAgra Foods, Inc. operates as a food company primarily in North America. The company operates through three segments: Consumer Foods, Commercial Foods, and Private Brands. The Consumer Foods segment provides branded food products in various categories, such as meals, entrees, condiments, sides, snacks, and desserts to various retail channels, such as frozen, refrigerated, and shelf-stable temperature classes. This segment’s principal brands comprise ACT II, Banquet, Blue Bonnet, Chef Boyardee, DAVID, Egg Beaters, Healthy Choice, Hebrew National, Hunt’s, Marie Callender’s, Orville Redenbacher’s, PAM, Peter Pan, Reddi-wip, Slim Jim, Snack Pack, Swiss Miss, Van Camp’s, and Wesson. The Commercial Foods segment offers frozen and sweet potato items, vegetable products, spices, bakery goods, and grain products to commercial, restaurants, foodservice, food manufacturing, and industrial customers under the Alexia, Lamb Weston, and Spicetec Flavors & Seasonings brands.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
